I don't believe any rebranding is running away from any history no matter how sordid or folly-full the initial acts were. AVII upset everyone with a reverse split then their CEO made himself enemy #1 of our friends at the FDA with several techniques. It took bringing in a new well known veteran CEO, a professional approach and a name change for AVII becoming SRPT to win approval for their drug Eteplirsen.
The rebranding is a clear signal to those that care, or are supposed to care (FDA) that this company is serious about its drug and going about getting it approved in the "correct' fashion. A company doesn't go to all this trouble for a weak drug.
Cyrus is following a script that has worked in the past. It should work for us because leronlimab is a significantly better drug candidate than most of the others out there.